The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients

被引:262
作者
Filipsson, Helena
Monson, John P.
Koltowska-Haggstrom, Maria
Mattsson, Anders
Johannsson, Gudmundur
机构
[1] Gothenburg Univ, Sahlgrenska Acad, Dept Endocrinol, SE-41345 Gothenburg, Sweden
[2] Queen Mary Univ London, St Bartholomews Hosp, London EC1A 7BE, England
[3] Pfizer, Endocrine Care, KIGS,KIMS,ACROSTUDY Med Outcomes, SE-19190 Sollentuna, Sweden
[4] Uppsala Univ, Dept Pharm, Uppsala, Sweden
关键词
D O I
10.1210/jc.2006-0524
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Hypopituitary patients with untreated GH deficiency and patients on inappropriately high doses of glucocorticoid ( GC) share certain clinical features. Objective: The aim of the study was to examine the influence of GC substitution on clinical characteristics in hypopituitary patients before and after GH replacement therapy. Method: A total of 2424 hypopituitary patients within the KIMS ( Pfizer International Metabolic Database) were grouped according to ACTH status. Comparisons were performed between subjects on hydrocortisone (HC) (n = 1186), cortisone acetate (CA) (n = 487), and prednisolone/dexamethasone (n = 52), and ACTH-sufficient patients (AS) (n = 717) before and after 1 yr of GH treatment in terms of body mass index, waist and hip circumference, blood pressure, glucose, glycosylated hemoglobin (HbA1c), serum lipids, IGF-I, and comorbidity. Hydrocortisone equivalent (HCeq) doses were calculated, and measurements were adjusted for sex and age. Results: At baseline, the HC group had increased total cholesterol, triglycerides, waist circumference, and HbA1c, and the prednisolone/ dexamethasone group had increased waist/hip ratio as compared with AS. After HCeq dose adjustment, the HC group retained higher HbA1c than the CA group. GC-treated patients showed a dose-related increase in serum IGF-I, body mass index, triglycerides, low-density lipoprotein cholesterol and total cholesterol levels. Subjects with HCeq doses less than 20 mg/d (n = 328) at baseline did not differ from AS in metabolic endpoints. The 1-yr metabolic response to GH was similar in all GC groups and dose categories. All new cases of diabetes (n = 12), stroke (n = 8), and myocardial infarction (n = 3) during GH treatment occurred in GC-treated subjects. Conclusion: HCeq doses of at least 20 mg/d in adults with hypopituitarism are associated with an unfavorable metabolic profile. CA replacement may have metabolic advantages compared with other GCs.
引用
收藏
页码:3954 / 3961
页数:8
相关论文
共 42 条
  • [1] GH replacement in 1034 growth hormone deficient hypopituitary adults:: demographic and clinical characteristics, dosing and safety
    Abs, R
    Bengtsson, BÅ
    Hernberg-Ståhl, E
    Monson, JP
    Tauber, JP
    Wilton, P
    Wüster, C
    [J]. CLINICAL ENDOCRINOLOGY, 1999, 50 (06) : 703 - 713
  • [2] EFFECT OF GLUCOCORTICOID REPLACEMENT THERAPY ON GLUCOSE-TOLERANCE AND INTERMEDIARY METABOLITES IN HYPOPITUITARY ADULTS
    ALSHOUMER, KAS
    BESHYAH, SA
    NITHTHYANANTHAN, R
    JOHNSTON, DG
    [J]. CLINICAL ENDOCRINOLOGY, 1995, 42 (01) : 85 - 90
  • [3] ENDOCRINE AND METABOLIC DISEASES - ADRENAL DISEASES
    BESSER, GM
    JEFFCOATE, WJ
    [J]. BRITISH MEDICAL JOURNAL, 1976, 1 (6007) : 448 - 451
  • [4] BOLAND EDWARD W., 1958, CALIFORNIA MED, V88, P417
  • [6] IGF-I levels rise and GH responses to GHRH decrease during long-term prednisone treatment in man
    Borges, MHS
    Pinto, ACAR
    DiNinno, FB
    Camacho-Hübner, C
    Grossman, A
    Kater, CE
    Lengyel, AMJ
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1999, 22 (01) : 12 - 17
  • [7] Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system:: Results from a multicenter study
    Brabant, G
    von zur Mühlen, A
    Wüster, C
    Ranke, MB
    Kratzsch, J
    Kiess, W
    Ketelslegers, JM
    Wilhelmsen, L
    Hulthén, L
    Saller, B
    Mattsson, A
    Wilde, J
    Schemer, R
    Kann, P
    [J]. HORMONE RESEARCH, 2003, 60 (02) : 53 - 60
  • [8] AMELIORATION OF INSULIN-RESISTANCE IN DIABETES WITH DEHYDROEPIANDROSTERONE
    BUFFINGTON, CK
    POURMOTABBED, G
    KITABCHI, AE
    [J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1993, 306 (05) : 320 - 324
  • [9] METABOLIC EFFECTS OF METACORTANDRALONE AND METACORTANDRACIN
    BUNIM, JJ
    BLACK, RL
    BOLLET, AJ
    PECHET, MM
    [J]. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1955, 61 (02) : 358 - 368
  • [10] Mechanisms of glucocorticoid action in bone: Implications to glucocorticoid-induced osteoporosis
    Canalis, E
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (10) : 3441 - 3447